NSL 9403

Drug Profile

NSL 9403

Latest Information Update: 15 Aug 2002

Price : $50

At a glance

  • Originator Nippon Steel
  • Class Anti-ischaemics; Antiplatelets; Oligopeptides; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Arterial thrombosis; Ischaemic heart disorders

Most Recent Events

  • 14 Nov 1997 A preclinical study has been added to the Thromboses pharmacodynamics section
  • 29 Jan 1997 Preclinical development for Ischaemic heart disorders in Japan (Unknown route)
  • 04 Nov 1996 A preclinical study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top